Viemed’s 2Q26 results strengthened the forward revenue profile, supported by record ventilator census growth and continued scaling across sleep, resupply, and women’s health. Revenue growth accelerated and cash generation improved, although a greater mix of lower-margin, less capital-intensive product and service revenue, alongside growth investments and temporary transition costs, pressured near-term profitability. Management raised the lower end of FY26 revenue guidance while modestly reducing EBITDA expectations, reflecting stronger demand but a slower margin ramp. The key focus into 2H26 is whether sustained ventilation growth and easing duplicate costs translate into improved productivity and operating leverage.